rss
Arch Dis Child 83:207-210 doi:10.1136/adc.83.3.207
  • Article

Prevalence and aetiology of hypothyroidism in the young

Abstract

AIMS To define the prevalence of hypothyroid disease in children and young people, and describe its aetiology.

METHODS We identified all patients on the Medicines Monitoring Unit (MEMO) database in the Tayside region of Scotland who had received two or more prescriptions for thyroxine during the study period (January 1993 to December 1995). Using this as a surrogate marker of hypothyroidism, we calculated the prevalence of hypothyroidism in those aged less than 22 years. Main outcome measures were prevalence of thyroxine prescription, estimated prevalence of hypothyroidism, and aetiology of the hypothyroidism (determined from case records, and biochemistry and immunology databases).

RESULTS Of 103 500 residents aged less than 22 years, 140 were identified as receiving thyroxine on prescription, giving a population prevalence of 0.135%. The ratio of male to female was 1:2.8. Acquired hypothyroidism was the commonest aetiology found in 73%, 66% of which had an autoimmune basis. The prevalence of congenital hypothyroidism was 0.027%. Seven had received treatment for malignancy (two primary thyroid). Fifteen per cent of patients had no record of secondary care follow up in Tayside.

CONCLUSIONS The overall prevalence of hypothyroidism in young people less than 22 years of age is 0.135%, and in the group aged 11–18 years it is 0.113%; these values are at least twice those of previous estimates. This suggests an increase in autoimmune thyroid disease, similar to the rising prevalence of type 1 diabetes, possibly indicating a rising incidence of autoimmunity in young people.

Prevalence rates for congenital hypothyroidism are well described, whereas acquired hypothyroidism in the young has been less well documented, particularly in recent years.

Primary congenital hypothyroidism has a comparable incidence worldwide (1:3000–1:4000 live births,1 with recent quoted figures in Holland of 1:3400 for primary congenital hypothyroidism and 1:25 000 for secondary hypothyroidism.2 In Scotland the incidence was estimated at 1:4350 births over the years 1980–1993.3 Of these approximately 2% (1:180 000 of all live births) have transient hypothyroidism secondary to maternal antibodies,4 and up to 5% may have transient hypothyroidism secondary to prematurity.5

Previous estimates of the prevalence of acquired hypothyroidism in children and adolescents, based on selected populations with few population studies, have ranged between 0.04% and 0.06%.6-8 Using Medline 1966–1999 we were unable to find any study describing the overall prevalence of clinical hypothyroidism in the 0–22 year age range.

Because thyroxine should be given to young people only if they are clinically and biochemically hypothyroid, prescription of the drug can be used as a surrogate marker of hypothyroidism. Our study aimed to define the population prevalence of patients receiving thyroxine prescription in young people less than 22 years of age, and from this the prevalence of hypothyroidism in the young.

Subjects and methods

SUBJECTS

The study population comprised all residents of the Tayside region of Scotland, less than 22 years of age on 1 January 1994, who were alive and remained resident in the region throughout the study period.

METHODS

Every patient who is registered with a general practitioner in Scotland is allocated a unique identifying number called the community health number (CHI) consisting of 10 digits, the first six being the date of birth. Every resident of Tayside is registered and appears in the centrally held, continuously updated computerised record, the Community Health Master Patient Index. This file contains data on patients' address and postcode, general practitioner, death, and date of death. Thus, the data analyse the demographic breakdown of the Tayside population, deaths, and patient migration. The CHI number is also used as the patient identifier in all healthcare activities in Tayside, both in primary and secondary care.

All prescriptions within the region (including thyroxine) are registered on a database generated by the Medicines Monitoring Unit (MEMO). This unit, based at Dundee University, has been described in detail elsewhere.9 10 Briefly, it has devised a method of capturing person specific dispensing for the whole of Tayside and, since January 1993, has recorded over 15 million prescription items specified by CHI number. From the MEMO database, we identified all prescriptions for thyroxine prescribed to all subjects less than 22 years of age between 1 January 1993 and 31 December 1994.

We inspected individual hospital case records (but not primary care case records), and clinical biochemistry and immunopathology computerised databases of the cohort to confirm the diagnosis and indication for thyroxine replacement. The following were also recorded: age at mid point of study (1 January 1994), age at diagnosis, sex, aetiology of clinical hypothyroidism, comorbidities, thyroid stimulating hormone (TSH) and serum thyroxine concentration at the time of diagnosis (reference ranges: TSH 0.4–4.0 mIU/l, free thyroxine 10–23 pmol/l; all tests performed in one laboratory in Tayside), autoantibody status (microsomal and thyroglobulin antibody tests, normal <1:40), and whether the subject was under primary care or hospital follow up. We regarded TSH greater than 4 mIU/l and free thyroxine less than 10 pmol/l as diagnostic of hypothyroidism. We excluded patients notified on the MEMO database as receiving only one thyroxine prescription during the study period. We obtained denominators for the calculation of the prevalence of thyroxine prescription from the community health master patient index. All patient ages were calculated at the mid point of the study period.

Results

Using the Tayside database, 103 500 young people less than 22 years of age were identified as living in Tayside between January 1993 and December 1995. During the study period, 140 children and adolescents received more than one prescription for thyroxine, giving a presumed population prevalence of hypothyroidism of 0.135%. There were 37 men and 103 women, a ratio of 1:2.8. Figure 1 shows the age distribution for thyroxine prescription.

Figure 1

Prevalence of thyroxine prescription for specific age groups; n = 140.

The aetiology was known in 85% of patients, and determined through examination of the hospital case records, where available, and record linkage using the patients' CHI numbers to clinical biochemistry and immunopathology records. Case records and biochemistry were available for 79% and case records only for 6%. Encashment of two or more prescriptions for thyroxine (presumed hypothyroid) was documented in the remaining 15%, but we identified no secondary care case records for these patients; however, 15% had biochemical evidence of hypothyroidism. The average age of this group was 16.9 years (range 7–22).

Acquired primary hypothyroidism was the commonest reason for thyroxine prescription in the cohort with a prevalence of 0.067%; fig 2 shows the remaining aetiologies and population prevalence. Of the cohort, 87 (73%) had an acquired cause of hypothyroidism; table 1 shows details of this group. The prevalence in young people aged 11–18 years for acquired hypothyroidism—that is, those patients who received thyroxine prescription, excluding congenital hypothyroidism and congenital panhypopituitary causes, was 0.113%.

Figure 2

Prevalence of thyroxine prescription in other aetiologies.

Table 1

Number, percentage, and disease aetiology of patients with acquired hypothyroidism

Of the children and young people with malignancy (n = 7), two had primary thyroid carcinoma diagnosed at 15 years, and one had a thyroidectomy for a cold nodule; the remainder had developed hypothyroidism secondary to treatment for other malignancies including Hodgkin's disease and leukaemia.

Of the 140 patients, 7.1% had a comorbidity, 3.5% had type 1 diabetes mellitus, 1.5% Down's syndrome, and 2.1% juvenile idiopathic arthritis.

Discussion

Our population based study has defined the prevalence of clinical hypothyroidism in young people less than 22 years of age in a geographically defined area. Previous studies have either been based on selected populations,6 11-14 or have investigated a population of later school age children (11–18 years of age).7 8 Thyroxine is only given to young people if they are clinically and biochemically hypothyroid, with the possible exception of reduction of a euthyroid goitre compressing surrounding structures. Using thyroxine prescription as a surrogate marker, therefore, will give absolute specificity for the prevalence of clinical hypothyroidism in this age group. Given that the database used to generate the patients receiving thyroxine, the case records, and clinical laboratory data set all use the CHI number, further validation of the database was possible.

Our study has defined a population prevalence for hypothyroidism of 135:100 000 for young people less than 22 years of age, two to three times higher than the previously published prevalence rate.6 In children of later school age (11–18 years of age) we have defined a prevalence of acquired hypothyroidism of 0.113%. A large prospective study performed in Utah and Arizona, USA in 1965–1968, with patients followed up as adults in 1985 to 1987, showed a population prevalence of 0.06% for hypothyroidism.7 A study of 5462 Croatian schoolchildren of the same age group, screened for thyromegaly and reported in 1994, contained five children (0.09%) with either an abnormal TSH or thyroxine value (or both). Three of these children (0.055%) were either overtly hypothyroid or had biochemical hypothyroidism. The remaining two children had increased TSH but normal thyroxine concentrations. None were on treatment with thyroxine before the study.8 The methodology of both these population studies was different to our own, in that they both identified thyroid abnormality by first screening the children for physical abnormality of the thyroid, whereas we identified hypothyroidism using treatment with thyroxine and would therefore expect to “miss” subclinical disease, and hence underestimate the prevalence of thyroid disease.

Our increased prevalence rate may represent variation in different parts of the world, but we note that the Utah/Arizona study showed a prevalence of hypothyroidism in adults of 1.6%,7 similar to the 1977 Whickham, UK survey of 1–1.5%.15

The majority of our cohort (66%) who had acquired hypothyroidism had an autoimmune basis for their disease, so our findings may reflect an increase in the prevalence of autoimmune thyroid disease. This appears to mirror the rising incidence of type 1 diabetes mellitus, seen in Scotland.16 Similarly, the prevalence of other diseases mediated through the immune system such as childhood allergies17 and asthma18-20 is currently rising in the young. It has been suggested that this may be caused by a decrease in exposure to infection in early life.21 22This hypothesis is supported by the demonstration that children from small families had an increased prevalence of atopy if they started day nursery at an older age.23 The anthroposophic lifestyle, including incomplete immunisation and less use of antibiotics, has recently been claimed to lead to a lower prevalence of allergic disease and atopy.24 Thus lifestyle and secular changes over recent years may be responsible for an increase in disease mediated through the immune system.

All causes of clinical hypothyroidism are represented in this cohort of children and young people, including two cases of thyroid carcinoma, which were both diagnosed when the patients were 15 years old. The prevalence of congenital primary hypothyroidism of 0.27% (27:100 000) was consistent with the incidence in Scotland over the last 20 years.5

No secondary care follow up was identified in 15% of the cases with an average age of 16.9 years. We presume that the majority of this cohort are either being followed exclusively in primary care or receiving specialist follow up outside Tayside.

Our study has shown that the cohort suffered from additional comorbitities. In 3.5% the hypothyroidism coexisted with type 1 diabetes mellitus, consistent with the known increased prevalence of other autoimmune conditions in this disorder. An additional 2% suffered from the combination of juvenile idiopathic arthritis and hypothyroidism, which raises the question of whether it might be of value to screen routinely for thyroid autoantibodies in juvenile idiopathic arthritis to detect the disease before clinical decompensation. In the cohort, 1.5% had Down's syndrome, confirming the well known association of these two conditions, and further justifying screening for hypothyroidism in Down's syndrome.

In summary, our study has defined a prevalence of clinical hypothyroidism in Tayside, Scotland which strongly suggests a rising prevalence of autoimmune thyroid disease in children and young people; we recommend further population studies to investigate this important finding.

References